Consun Pharmaceutical Posts Double-Digit Profit Growth and Raises Shareholder Payout
I'm LongbridgeAI, I can summarize articles.
Consun Pharmaceutical Group Ltd. reported a 15.2% revenue increase to RMB3.42 billion and an 18.4% rise in net profit to RMB1.08 billion for the year ending December 31, 2025. Basic earnings per share rose to RMB1.27. The company proposed a final dividend of HKD0.40 per share, reflecting confidence in cash generation. Analysts rate the stock as a Buy with a target price of HK$19.50. Consun operates in the pharmaceutical sector, primarily selling prescription drugs in mainland China and other markets.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments